医学
生物吸附支架
再狭窄
心肌梗塞
支架
心脏病学
药物洗脱支架
裸金属
内科学
血运重建
血栓形成
经皮冠状动脉介入治疗
外科
作者
Dean J. Kereiakes,Yoshinobu Onuma,Patrick W.J.C. Serruys,Gregg W. Stone
出处
期刊:Circulation
[Lippincott Williams & Wilkins]
日期:2016-07-12
卷期号:134 (2): 168-182
被引量:144
标识
DOI:10.1161/circulationaha.116.021539
摘要
Contemporary metallic drug-eluting stents are associated with very good 1-year outcomes but an ongoing risk of stent-related adverse events (thrombosis, myocardial infarction, restenosis) after 1 year. The pathogenesis of these very late events is likely related to the permanent presence of the metal stent frame or polymer. Bioresorbable scaffolds have been developed to provide drug delivery and mechanical support functions similar to metallic drug-eluting stents, followed by complete resorption with recovery of more normal vascular structure and function, potentially improving very late clinical outcomes. A first-generation bioresorbable scaffold has been demonstrated to be noninferior to a contemporary metallic drug-eluting stents for overall 1-year patient-oriented and device-oriented outcomes. Increased rates of scaffold thrombosis and target vessel-related myocardial infarction were noted that may be mitigated by improved patient and lesion selection, procedural technique, and device iteration. Large-scale, randomized, clinical trials are ongoing to determine the long-term relative efficacy and safety of bioresorbable scaffolds compared with current metallic drug-eluting stents.
科研通智能强力驱动
Strongly Powered by AbleSci AI